ImmunityBio Clears Trial Power Check but FDA Warning Clouds Anktiva Path
NEW YORK, April 2 —
ImmunityBio (IBRX) passed the statistical power threshold in its pivotal BCG-naïve bladder cancer trial for ANKTIVA. The same week, the FDA issued a warning on the drug. The stock closed at $7.14.
- Pivotal randomized trial of ANKTIVA + BCG vs. BCG alone cleared its statistical power check in BCG-naïve non-muscle invasive bladder cancer (NMIBC)
- IBRX trades at $7.14 with a -357x forward P/E on just $113mn TTM revenue — the entire valuation is the pipeline
- Next catalyst: FDA response to ImmunityBio's supplemental filing and resolution timeline on the warning letter
What Actually Happened
Two things happened, and they cut against each other. First: ANKTIVA's randomized trial in BCG-naïve NMIBC patients passed its pre-specified statistical power check. The trial has enrolled enough events to produce a valid readout comparing ANKTIVA plus BCG against BCG alone. This is the front-line bladder cancer population — not the BCG-unresponsive niche where Anktiva already has FDA approval. A positive result would open a far larger patient pool.
Second: the FDA issued a warning related to Anktiva that puts the drug's regulatory standing in question. ImmunityBio said it plans to submit supplemental data to support clinical meaningfulness — which means the FDA raised concerns the company now has to answer. ImmunityBio has not disclosed what the warning specifically covers. That silence is its own signal.
The Catch
A statistical power check is not efficacy data. It confirms the trial can produce a statistically valid answer. It says nothing about what that answer will be. Investors treating this as a win are cheering that the exam has enough questions to be gradable. The actual grade comes later.
The FDA warning, by contrast, is concrete and present. At -357x forward P/E, the stock has no margin of safety. The $113mn in TTM revenue comes almost entirely from existing Anktiva sales in the BCG-unresponsive setting — sales the FDA warning itself could threaten.
Bottom Line
This is a binary setup. The trial power confirmation keeps the bull case intact. The FDA warning keeps the bear case just as alive. Neither event settles the question alone, but together they pin the stock to a narrow range until the FDA responds. This is a position for biotech specialists with specific conviction on the regulatory outcome, not for generalists. The only date that matters now is when the FDA answers ImmunityBio's supplemental filing.
For a full financial breakdown on ImmunityBio, generate a Basis Report on IBRX here.
Basis Report does not hold positions in securities discussed. This is not investment advice.